BMJ Open Cohort profile: the Swiss Mother and **Child HIV Cohort Study (MoCHiV)**

Paolo Paioni,¹ Murezi Capaul,² Anja Brunner,³ Anna Traytel,^{2,4} Karoline Aebi-Popp,^{5,6} Pierre-Alex Crisinel,⁷ Andrea Duppenthaler,⁸ Huldrych Günthard,² Begona Martinez De Tejada,⁹ Lisa Kottanattu,¹⁰ Marcel Stöckle,¹¹ Andri Rauch,⁵ Noemie Wagner,¹² Irene Hösli,¹³ Christoph Rudin,¹⁴ Alexandra Scherrer,² Katharina Kusejko,² Christian R Kahlert ¹⁰, ^{15,16} Swiss HIV Cohort Study (SHCS) and the Swiss Mother and Child HIV Cohort Study (MoCHiV)

ABSTRACT

Purpose Prospective, multicentric observational cohort study in Switzerland investigating measures to prevent mother-to-child transmission in pregnant women with HIV (WWH) and assessing health and development of their exposed children as well as of children with HIV (CWH) in general.

Participants Between January 1986 and December 2022, a total of 1446 mother-child pairs were enrolled. During the same period, the study also registered 187 CWH and 521 HIV-exposed but uninfected children (HEU), for whom detailed maternal information was not available. Consequently, the cohort comprises a total of 2154 children.

Findings to date During these 37 years, research by the Swiss Mother and Child HIV Cohort Study (MoCHiV) and its international collaborators has strongly influenced the prevention of vertical transmission of HIV (eg, introduction and discontinuation of elective caesarean section, neonatal postexposure prophylaxis and breastfeeding). Contributions have also been made to the management of diagnostics (eq, p24 antigen assay) and the effects of antiretroviral treatment (eg, prematurity, growth) in HEU and CWH. Future plans Most children present within the cohort are now HEU, highlighting the need to investigate other vertically transmitted pathogens such as hepatitis B and C viruses, cytomegalovirus or Treponema pallidum. In addition, analyses are planned on the longitudinal health status of CWH (eg, resistance and prolonged exposure to antiretroviral therapy), on social aspects including stigma in CWH and HEU, and on interventions to further optimise antenatal and postpartum care in WWH.

icant challenge globally. According to the

2023 UNAIDS Fact Sheet, there are approx-

transmission of HIV as a matter of global

concern. While the highest prevalence of

STRENGTHS AND LIMITATIONS OF THIS STUDY

- \Rightarrow Prospective longitudinal data collection over more than 30 years and across generations, combining clinical, behavioural and laboratory data in conjunction with a biobank.
- \Rightarrow Transfer of a large proportion of children with HIV in MoCHiV to the adult cohort allows vertically infected children to be followed well into adulthood.
- \Rightarrow Standardised guestionnaires, monitored data management and close cooperation with the Swiss HIV Cohort Study (SHCS) data centre quarantee highquality longitudinal data.
- \Rightarrow Fully standardised data are only available from 2004 as different databases have been used and had to be brought together as part of the development of MoCHiV and its integration into the SHCS and because various questionnaires were introduced at different times.
- \Rightarrow Possible selection bias, as around 30% of pregnant women with HIV registered by the Swiss Federal Office of Public Health do not participate in the SHCS.

paediatric HIV infection is observed in suband Saharan Africa, the global spread of the HIV pandemic, exacerbated in part by refugee movements, underscores the universal need for ongoing research into the prevention, diagnosis and treatment of HIV during pregnancy and among children affected. This still necessitates a concerted global effort to address HIV in all countries.

The Swiss Mother and Child HIV Cohort Study (MoCHiV) contributes as a nationwide ongoing prospective, multicentric, observational study following pregnant women living with HIV (WWH) and their children. In synergy with the Swiss HIV Cohort Study (SHCS, www.shcs.ch),¹² its focus is on interdisciplinary clinical and translational research, epidemiological and social science and public health questions. MoCHiV provides

BMJ Open: first published as 10.1136/bmjopen-2024-086543 on 23 September 2024. Downloaded from http://bmjopen.bmj.com/ on June 8, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) Protected by copyright, including for uses related text and data miníng, Al training,

8

To cite: Paioni P, Capaul M, Brunner A. et al. Cohort profile: the Swiss Mother and Child HIV Cohort Study (MoCHiV). BMJ Open 2024:14:e086543. doi:10.1136/ bmjopen-2024-086543

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2024-086543).

Received 17 March 2024 Accepted 29 August 2024

INTRODUCTION Check for updates The HIV pandemic continues to pose a signif-

C Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to Christian R Kahlert: christian.kahlert@kispisg.ch




Figure 1 Overview of studies, numbers and introduction of standardised questionnaires over time. SHCS, Swiss HIV Cohort Study.

access to a unique longitudinal data collection on WWH before, during and after pregnancy and delivery as well as on their offspring and on children with HIV (CWH). The primary objective is to evaluate and improve prevention against vertical transmission of HIV and secure optimal care of pregnant WWH and their exposed children, as well as of CWH. Epidemiological and psychosocial aspects are also examined, as are the multiple pharmacological exposures during pregnancy and childhood.

COHORT DESCRIPTION

Setting, locations and relevant dates

Two separate cohort studies existed in the 1980s: The Swiss Neonatal HIV Study,³ established in 1986, focused on paediatric HIV issues and the natural history of the infection in CWH. The Swiss HIV and Pregnancy Study,⁴ established in 1989, 1 year after the SHCS, focused on pregnant WWH and maternal or obstetric risk factors for vertical transmission. In 1999, these cohorts were combined to form a single mother and child cohort, named MoCHiV, which enrolled and followed pregnant WWH and their offspring (figure 1). In 2003, MoCHiV was integrated into the SHCS. Data are collected in seven centres (five Swiss university hospitals situated in Basel, Bern, Geneva, Lausanne and Zurich, and two cantonal reference hospitals situated in St. Gallen and Lugano), including private physicians and regional hospitals, which send their questionnaires to the nearest referral centre. Blood samples collected according to the study protocol

are stored in a biobank at one of three central laboratories situated in Basel, Geneva and Zurich. The coordination and data centre in Zurich manages both cohort studies.

Eligibility and follow-up

data mini Participants eligible for inclusion in the cohort are (1) ģ pregnant WWH who are registered in the SHCS, along ≥ with their children who are exposed to HIV and (2) CWH, regardless of whether their mothers are included in the SHCS. Subject to receipt of the signed consent ĝ forms, all pregnancies and children registered in the participating centres will be systematically included in this cohort. Pregnant WWH are followed semiannually <u>0</u> according to the SHCS protocol and supplementary visits take place during pregnancy for antenatal care including monitoring of the HIV plasma viral load (pVL).

During the first 6months of life, all children born to lour WWH have the same clinical follow-up. Diagnostic blood samples were initially taken at 1, 2 and 6 months of age. In recent years, due to the availability of more accurate **8** HIV tests, only two samples at 1 and 6 months are taken to rule out vertical transmission of HIV by HIV RNA PCR. Additionally, at the age of 18-24 months, a negative antibody screening test is required. According to their HIV status, exposed children are followed according to separate follow-up programmes. CWH are examined every 6months with in-depth information on laboratory and clinical parameters. HEU are followed every 6months until 1 year of age, and then annually until 5 years of age

Protected by copyright, including for uses related to text and

(online supplemental figure 1) to assess growth and clinical events potentially related to combination antiretroviral therapy (cART) exposure in utero, through neonatal postexposure prophylaxis (nPEP) or breastfeeding.

CWH are offered to be transferred to the SHCS at the age of 18 years. There is no standardised transition programme, the process can vary between centres. However, a special questionnaire is used to collect information about participant's drop-out, such as loss to follow-up or death. Clinical care is the same for all mothers and children, regardless of whether they are included in MoCHiV and/or the SHCS.

Data collection

Until 2022, data have been prospectively collected via paper forms and submitted by mail to the data centre of the SHCS, where data managers transferred them manually to an Oracle database. During the second half of 2022, a user-friendly graphical user interface for electronic data collection at the local study sites was implemented and database migration to a Research Electronic Data Capture-based database (REDCap) was performed.⁵

Regarding the variables of interest, for pregnant women participating in the SHCS, we collected data on socioeconomic and educational background, general physical and mental health condition, relevant medical history, coinfections, comorbidities, specific HIV or AIDSrelated diseases, current and past antiretroviral therapy, other medications, alcohol, nicotine or drug use as well as information about gynaecological and pregnancy history. Additionally, blood samples are regularly taken and stored in a biobank (plasma stored at -80°C and peripheral blood mononuclear cells (PBMCs) at - 160°C). During pregnancy, WWH participating in MoCHiV complete a structured pregnancy and delivery questionnaire, covering obstetric history, pregnancy complications and specific morbidity during each trimester of pregnancy and childbirth.

For children, the newborn questionnaire collects data on general health status, medication and feeding. Blood samples are taken at 1, 2 (not in all centres) and 6 months of age to rule out vertical transmission of HIV by HIV RNA PCR. Additionally, at the age of 18-24 months, a negative antibody screening test is required. The follow-up questionnaire includes anthropometry, social situation, health status, medication and nutrition. For CWH, information on HIV-associated diseases, treatment and laboratory results of haematological, biochemical and virological parameters is reported. Additionally, leftover routine blood samples are stored in a biobank as described above. For example, in 2022, 95 plasma samples and 73 PBMCs samples from children have been stored in our biobank.

Consent and representativeness for Switzerland

Pregnant WWH participating in the SHCS sign an additional informed consent to participate in MoCHiV for themselves and simultaneously for their unborn child. All children born to WWH who signed the MoCHiV informed

consent are enrolled, irrespective of their infection status. In addition, any CWH can participate, even if the mother is not known or not followed up in the SHCS.

SHCS and MoCHiV are highly representative of the group of pregnant WWH with an estimated coverage of 71% of all people with HIV (PWH) on cART in Switzerland.² Overall, 86.1% (1041 of 1209) of the women giving birth enrolled in the SHCS agreed to participate in MoCHiV.

Tables 1 and 2 present the cumulative numbers of \neg the study participants and their characteristics. Online supplemental table 2 shows the cumulative numbers of mothers registered in the SHCS. Most reported charac-Š teristics are comparable between mothers participating in copyright, the SHCS only and mothers additionally participating in both SHCS and MoCHiV.

Numbers of pregnant WWH and vertical transmission

Between January 1986 and December 2022, a total of 1041 pregnant WWH were registered in MoCHiV. Median age of women at birth of their first child was 30 years (IQR 25-35) and median age at HIV diagnosis was 26 years (IQR 23–31). 27.7% (288 of 1041) of the WWH were first uses r diagnosed during pregnancy. The most common mode of HIV infection was heterosexual transmission in 78.6% of the women (818 of 1041), followed by intravenous drug use in 14.6% (152 of 1041) and vertical transmission in 1.7% of the cases (18 of 1041). Ethnicities are represented as follows: 43.7% (455 of 1041) black, 42.7% (445 e of 1041) white, 6.2% (65 of 1041) Asian and 3.6% (37 of 1041) Hispano-American. There were 15% (328 of 2154) preterm deliveries (<37+0 weeks of gestation), of which ő 71% (233 of 328) were late preterm births (between \overline{a} 34+0 and 36+6 weeks of gestation).

A total of 1446 children were born from the 1041 WWH mentioned above, with 335 mothers having more than ≥ one child registered (280 mothers having 2, 42 mothers training, having 3, 11 mothers having 4 and 2 mothers having 5 children registered). In total, 25 twins and 1 triplet were born. Overall, 98 children turned out to be diagnosed and similar with HIV resulting in an overall vertical transmission frequency of 6.8% (98 of 1446) spanning 37 years.

Numbers of HIV-exposed children and CWH

Between January 1986 and December 2022, cumulative data on 2154 children were registered in MoCHiV, of whom 285 were CWH and 137 had an unknown infection status. In addition to the 1446 children mentioned $\mathbf{\mathring{G}}$ above (1348 HIV-exposed children, 98 CWH), data of 3 708 (521 HIV-exposed children and 187 CWH) children without detailed information about the mother have been collected. On the other hand, a total of 285 CWH were enrolled, of which 95 (of 285, 33.3 %) were lost to follow-up or voluntarily withdrew from the study (eg, changed to a physician not participating in the SHCS), 61 (of 285, 21.4 %) died and 16 (of 285, 5.6%) are currently still being followed. 113 of 285 (39.6 %) children have reached adulthood and are now followed within the

	Total	Zurich	Lausanne	Geneva	Basel	Bern	St. Gallen	Ticino
Nothers								
	1041	287	196	180	149	153	58	42
Total registered mothers								
Active patients	647 (62%)	150 (52%)	127 (65%)	115 (64%)	95 (64%)	107 (70%)	43 (74%)	24 (57%)
Voluntary Discontinuation	109 (10%)	28 (10%)	19 (10%)	24 (13%)	14 (9%)	15 (10%)	4 (7%)	8 (19%)
Died	55 (5%)	23 (8%)	3 (2%)	11 (6%)	7 (5%)	7 (5%)	4 (7%)	1 (2%)
Lost to follow-up	230 (22%)	86 (30%)	47 (24%)	30 (17%)	33 (22%)	24 (16%)	7 (12%)	9 (21%)
ge in years at HIV diagno	sis							
Median (IQR)	26 (23–31)	26 (23–30)	27 (23–31)	26 (23–31)	26 (23–30)	27 (2–32)	27 (23–30)	27 (24–30)
ge in years at birth of the	first child in S	SHCS						
Median (IQR)	30 (25–35)	30 (25–35)	31 (26–35)	29 (26–35)	30 (25–34)	29 (25–34)	30 (26–33)	32 (28–36)
thnicity	, ,	, , , , , , , , , , , , , , , , , , ,	. ,	. ,	· · · ·	. ,	, ,	
Black	455 (44%)	86 (30%)	111 (57%)	96 (53%)	58 (39%)	86 (56%)	23 (40%)	4 (10%)
White	445 (43%)	164 (57%)	73 (37%)	63 (35%)	64 (43%)	47 (31%)	21 (36%)	26 (62%)
Asian	65 (6%)	19 (7%)	3 (2%)	4 (2%)	14 (9%)	13 (8%)	7 (12%)	6 (14%)
Hispano-American	37 (4%)	14 (5%)	5 (3%)	3 (2%)	5 (3%)	4 (3%)	2 (3%)	4 (10%)
Unknown	39 (4%)	4 (1%)	4 (2%)	14 (8%)	8 (5%)	3 (2%)	5 (9%)	2 (5%)
Source of HIV infection		. (. , . ,	. (_ , . ,	(.,)		- (- / - /	- (-,-)	_ (- , - ,
Heterosexual contact	818 (79%)	205 (71%)	165 (84%)	146 (81%)	115 (77%)	124 (81%)	44 (76%)	34 (81%)
Intravenous drug use	152 (15%)	66 (23%)	15 (8%)	18 (10%)	26 (17%)	14 (9%)	11 (19%)	8 (19%)
Perinatal transmission	18 (2%)	6 (2%)	5 (3%)	5 (3%)	1 (1%)	0 (0%)	1 (2%)	0 (0%)
Blood products	14 (1%)	3 (1%)	4 (2%)	4 (2%)	2 (1%)	1 (1%)	1 (2%)	0 (0%)
Unknown	39 (4%)	7 (2%)	7 (4%)	7 (4%)	5 (3%)	14 (9%)	1 (2%)	0 (0%)
iral load at delivery (n=14						14 (070)	1 (270)	0 (070)
Nr of deliveries	1446	388	266	258	201	203	76	54
<50 copies/mL	814 (56%)	211 (54%)	149 (56%)	145 (56%)	113 (56%)	128 (63%)	36 (47%)	32 (59%)
50–1000 copies/mL	132 (9%)	34 (9%)	29 (11%)	19 (7%)	14 (7%)	20 (10%)	9 (12%)	7 (13%)
>1000 copies/mL	79 (5%)	27 (7%)	17 (6%)	5 (2%)	14 (7 %)	6 (3%)	4 (5%)	2 (4%)
Unknown								
Children	421 (29%)	116 (30%)	71 (27%)	89 (34%)	56 (28%)	49 (24%)	27 (36%)	13 (24%)
Shildren	0154	501	202	0.05	204	000	110	102
atal registered shildren	2154	591	393	335	324	298	110	103
otal registered children	115 (50/)	22 (60/)	20 (70/)	06 (00/)	14 (40/)	4 (10/)	F (F0/)	4 (407)
Active patients	115 (5%)	33 (6%)	29 (7%)	26 (8%)	14 (4%)	4 (1%)	5 (5%)	4 (4%)
Transition to SHCS	113 (5%)	29 (5%)	17 (4%)	21 (6%)	18 (6%)	18 (6%)	8 (7%)	2 (2%)
Completed follow-up	1247 (58%)	373 (63%)	245 (62%)	167 (50%)	189 (58%)	139 (47%)	63 (57%)	71 (69%)
Voluntary discontinuation	101 (5%)	49 (8%)	13 (3%)	16 (5%)	7 (2%)	10 (3%)	2 (2%)	4 (4%)
Died*	81 (4%)	31 (5%)	14 (4%)	11 (3%)	6 (2%)	9 (3%)	2 (2%)	8 (8%)
Lost to follow-up	497 (23%)	76 (13%)	75 (19%)	94 (28%)	90 (28%)	118 (40%)	30 (27%)	14 (14%)
nfection status								
Exposed uninfected	1732 (80%)	488 (83%)	331 (84%)	246 (73%)	249 (77%)	248 (83%)	88 (80%)	82 (80%)
Infected	285 (13%)	81 (14%)	47 (12%)	52 (16%)	37 (11%)	37 (12%)	16 (15%)	15 (15%)
Unknown	137 (6%)	22 (4%)	15 (4%)	37 (11%)	38 (12%)	13 (4%)	6 (5%)	6 (6%)
Sex								

Table 1 Continued

	Total	Zurich	Lausanne	Geneva	Basel	Bern	St. Gallen	Ticino
Male	1099 (51%)	315 (53%)	191 (49%)	161 (48%)	161 (50%)	161 (54%)	57 (52%)	53 (51%)
Female	1055 (49%)	276 (47%)	202 (51%)	174 (52%)	163 (50%)	137 (46%)	53 (48%)	50 (49%)
Node of delivery								
Caesarean	916 (43%)	309 (52%)	140 (36%)	131 (39%)	119 (37%)	127 (43%)	47 (43%)	43 (42%)
Vaginal	383 (18%)	56 (9%)	74 (19%)	105 (31%)	64 (20%)	58 (19%)	23 (21%)	3 (3%)
Unknown	855 (40%)	226 (38%)	179 (46%)	99 (30%)	141 (44%)	113 (38%)	40 (36%)	57 (55%)
Preterm birth								
Full-term birth	1652 (77%)	421 (71%)	297 (76%)	270 (81%)	258 (80%)	248 (83%)	78 (71%)	80 (78%)
Preterm birth	328 (15%)	119 (20%)	54 (14%)	43 (13%)	46 (14%)	29 (10%)	21 (19%)	16 (16%)
Unknown	174 (8%)	51 (9%)	42 (11%)	22 (7%)	20 (6%)	21 (7%)	11 (10%)	7 (7%)

SHCS.² The median age at the last visit to MoCHiV before transfer to the SHCS was 18.0 years (IQR 16.5-18.8).

Findings to date

Vertical transmission of HIV has been significantly reduced to less than 1% in high-income countries over the past 30 years. This has been achieved through the introduction of various prevention measures, most importantly effective maternal cART. This was accompanied by corresponding changes in guidelines and standards of care, such as the change in recommended mode of delivery to elective caesarean section (eCS) or, later, the introduction of effective cART during pregnancy. Research from MoCHiV and its international collaborators has strongly influenced the recommendations of prevention measures over the past decades. MoCHiV is collaborating among others with the European Collaborative Study (ECS), the PENTA Foundation, the HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS), the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) and the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER).

In 1994, the Pediatric AIDS Clinical Trials Group Protocol (PACTG-076) Study Group published the first important general results on the reduction of vertical transmission of HIV. Zidovudine given orally during pregnancy, intravenously during delivery and orally to the newborn for 6 weeks reduced vertical transmission by two-thirds to 8% (PACTG-076).⁶ Based on these findings the Swiss Pediatric AIDS-Group recommended to offer zidovudine chemoprophylaxis to all pregnant WWH and their neonates in Switzerland in November 1994.⁷

Subsequently, the protective effect of eCS, before rupture of membranes and onset of labour has been demonstrated by Kind et al using data from the Swiss Neonatal HIV Study.⁸ ⁹ In 1998, the same study group presented their results on the cumulative protective effect of both the eCS and the zidovudine chemoprophylaxis.¹⁰

Two international collaborative studies including data from the former two MoCHiV studies (the Swiss HIV and Pregnancy Study and the Swiss Neonatal HIV Study) confirmed these results in 1999.^{11 12} re

In the mid-1990s, new antiretroviral agents and combined treatment were introduced into clinical care. By combining three drugs including a protease inhibitor, antiretroviral treatment for the first time achieved ö complete suppression of HIV pVL in most patients. These new treatments and strategies were rapidly introduced into the SHCS with remarkable success at the population level: in 1999 90.7% of SHCS participants achieved an undetectable pVL (cut-off at that time<400 HIV-RNA copies/mL) after 12 months of treatment.¹³¹⁴

Initial concerns about the adverse effects of antiretrovirals on the unborn child have been refuted in various ⊳ studies, among others by Lorenzi et al with data from the Swiss Neonatal HIV Study and the Swiss HIV and Pregnancy Study.¹⁵ In 1998, the Swiss guidelines were adapted and cART became the standard of care for pregnant WWH.¹⁶ This change in treatment regimen reduced **B** HIV pVL to below the detection limit in the majority of WWH. As a result, the general recommendation of eCS for all pregnant WWH has been questioned in the light of outcome studies showing increased complication rates compared with vaginal delivery. In 2006, data from MoCHiV demonstrated that minor complications were eightfold more common in WWH undergoing an eCS than in WWH with vaginal delivery and this was independent of CD4 cell count or HIV pVL at the time of delivery.¹⁷ Accordingly, in 2009, Switzerland changed its guidelines and recommended vaginal delivery for women under cART during pregnancy and with undetectable HIV pVL near the time of delivery. Under these conditions, pregnant WWH can be managed in the same way as HIV-uninfected women.¹⁸¹⁹ The corresponding decrease in eCS after 2009 is shown in figure 2. Also based on

ð

uses

lated

ā

Open access

	Total	Zurich	Lausanne	Geneva	Basel	Bern	St. Gallen	Ticino
CWH included in MoCHiV								
	285	81	47	52	37	37	16	15
Total infected children								
Active patients	16 (6%)	9 (11%)	5 (11%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (13%)
Transition to SHCS	113 (40%)	29 (36%)	17 (36%)	21 (40%)	18 (49%)	18 (49%)	8 (50%)	2 (13%)
Voluntary discontinuation	15 (5%)	6 (7%)	2 (4%)	4 (8%)	2 (5%)	1 (3%)	0 (0%)	0 (0%)
Died*	61 (21%)	23 (28%)	10 (21%)	7 (13%)	6 (16%)	5 (14%)	2 (12%)	8 (53%)
Lost to follow-up	80 (28%)	14 (17%)	13 (28%)	20 (38%)	11 (30%)	13 (35%)	6 (38%)	3 (20%)
Participation of mother in SHCS								
No participation	187 (66%)	56 (69%)	32 (68%)	31 (60%)	27 (73%)	23 (62%)	6 (38%)	12 (80%)
Participation	98 (34%)	25 (31%)	15 (32%)	21 (40%)	10 (27%)	14 (38%)	10 (62%)	3 (20%)
Age of inclusion								
At birth	75 (26%)	20 (25%)	11 (23%)	15 (29%)	12 (32%)	4 (11%)	4 (25%)	60%) (%09)
Later	210 (74%)	61 (75%)	36 (77%)	37 (71%)	25 (68%)	33 (89%)	12 (75%)	6 (40%)
Median age at inclusion if later (IQR)	3.8 (1.2–8.2)	2.5 (0.9–5.1)	5.6 (2.1–10.6)	5.9 (3.5–10.6)	4 (0.9–10)	3.4 (1.6–6.3)	4.2 (1.2–6.3)	2 (0.8–3)
Sex								
Female	150 (53%)	42 (52%)	25 (53%)	29 (56%)	21 (57%)	16 (43%)	7 (44%)	10 (67%)
Male	135 (47%)	39 (48%)	22 (47%)	23 (44%)	16 (43%)	21 (57%)	9 (56%)	5 (33%)
Ethnicity								
White	82 (29%)	28 (35%)	15 (32%)	11 (21%)	12 (32%)	13 (35%)	2 (12%)	1 (7%)
Black	74 (26%)	9 (11%)	14 (30%)	21 (40%)	15 (41%)	7 (19%)	6 (38%)	2 (13%)
Hispano-American	13 (5%)	2 (2%)	3 (6%)	3 (6%)	0 (0%)	2 (5%)	3 (19%)	0 (0%)
Asian	8 (3%)	2 (2%)	0 (0%)	2 (4%)	1 (3%)	2 (5%)	1 (6%)	0 (0%)
Unknown	108 (38%)	40 (49%)	15 (32%)	15 (29%)	9 (24%)	13 (35%)	4 (25%)	12 (80%)
Source of HIV infection								
Vertical transmission	217 (76%)	59 (73%)	37 (79%)	47 (90%)	24 (65%)	29 (78%)	12 (75%)	60%) (%09)
Blood products	4 (1%)	1 (1%)	2 (4%)	1 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Heterosexual contact	1 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)
Unknown	63 (22%)	21 (26%)	8 (17%)	4 (8%)	12 (32%)	8 (22%)	4 (25%)	6 (40%)
Median follow-up time in years								
Median (IQR)	8.3 (2.0–15)	7.9 (1.5–16)	6.9 (2.2–12)	9.2 (2.6–15)	9.4 (3.1–16)	11 (5.8–15)	4.1 (0–13)	1.3 (0–10)

6

Paioni P, et al. BMJ Open 2024;14:e086543. doi:10.1136/bmjopen-2024-086543

6




Figure 2 Number of newly infected children, children receiving neonatal postexposure prophylaxis (nPEP) and mode of delivery over time.

MoCHiV data, the association between cART and a higher rate of premature delivery was first reported by Lorenzi *et al.*¹⁵ In the following years, a study from Switzerland based on MoCHiV data and a collaborative study of three observational studies from the USA, the UK and the European Collaborative Study confirmed that cART during pregnancy was indeed associated with an increased risk of late preterm delivery compared with no therapy or antiretroviral monotherapy.^{20 21} The most recent analysis of all registered pregnancies in MoCHiV showed that the rate of preterm delivery in WWH has decreased in Switzerland between 1986 and 2020, but remains twice as high as in the general population.²²

New, more effective agents should, therefore, always be assessed for safety in exposed children. In a collaborative project with the Pediatric HIV/AIDS Cohort Study in the USA, dolutegravir-based cART was shown to be safe and effective during pregnancy.²³

By following HIV-exposed uninfected children (HEU) up to the age of 5 years, MoCHiV contributed to assess the short and long-term effects of intrauterine exposure to cART during pregnancy.^{15 20 24} A single-centre evaluation from Zürich showed that HEU receiving nPEP with zidovudine had nonsignificant trends of lower CD4 and CD8 T cells and CD19 B-cells than those who did not. This suggests toxicity that could affect the overall health of these children.²⁵

The improvement of diagnostic procedures was another important research field of MoCHiV. As one of the first cohorts, the Swiss Neonatal HIV Study described repeated PCR to recognise perinatal HIV infection.²⁶ Another important achievement was the development of heat-denatured p24 antigen assay by Schüpbach *et al*, using material collected by the Swiss Neonatal HIV study.²⁷⁻³⁰

In addition to eCS and maternal antiretroviral therapy, other measures to prevent vertical transmission of HIV include nPEP and formula feeding. These measures

Protected by copyright, including have also been questioned in the light of highly effective maternal antiretroviral therapy. In 2016, Switzerland became the first country worldwide to recommend disconuses rela tinuation of the nPEP in newborns born to WWH with fully suppressed HIV pVL at the time of delivery, irrespective of the mode of delivery. This recommendation was issued by a working group of MoCHiV members together with the Federal Office of Public Health (FOPH).³¹ The implementation of the new recommendation was e presented at the 17th European AIDS Conference (EACS 2019) in Basel (Abstract PS1/5).³² The rapidly decreasing number of newborns receiving nPEP after 2016 is shown 0 in figure 2.

In 2018, new guidelines on breastfeeding in WWH were published. This made Switzerland the first country in a resource-rich setting to no longer rigidly discourage breastfeeding in WWH, provided certain defined condi-≥ tions are met and monitoring is ensured.³³ These conditions are referred to as the 'optimal scenario' and include a fully suppressed maternal HIV viral load throughout pregnancy. If the optimal scenario conditions are met, breastfeeding is supported if the mother wishes to breastfeed. However, the decision is preceded by a shared decision-making process to ensure that the pregnant woman fully understands the risks and benefits of breastfeeding in HIV. Thus, there is currently no recommendation for breastfeeding with HIV in Switzerland. The implementation of the new approach was analysed in a g study describing the main motivational factors of WWH enrolled in MoCHiV who decided to breastfeed after a shared decision-making process.³⁴ At the same time, the transfer of antiretroviral drugs into breast milk and the corresponding drug exposure of the infant were measured in the same patients.³⁵ Additionally, retention in HIV care and viral suppression during the critical postpartum period has been assessed in MoCHiV overall³⁶ and for the population of WWH with undetectable HIV pVL around the time of delivery,³⁷ showing reassuringly

าd data

Ĵ

≥

high rates of both in the group of WWH with undetectable HIV pVL.

Based on the findings of the MoCHiV Cohort Study in the context of global research, the recommendations in Switzerland have constantly been adapted over the past decades. Figure 2 illustrates the changes in the Swiss recommendations, that is, the introduction and discontinuation of prevention measures against and a significant reduction in vertical transmission of HIV. This is illustrated by the decreasing number of newly infected children born to mothers registered in the SHCS database over time.

By following CWH up to the age of 18, the MoCHiV Study was involved in the investigation of HIV disease characteristics and therapy in children. Rudin et al evaluated the long-term safety and effectiveness of PI-based treatment regimes in CWH.^{38 39} MoCHiV early described catch-up growth in CWH after initiation of antiretroviral treatment with highly active antiretroviral therapy including protease inhibitors.⁴⁰⁻⁴² The unique setting of MoCHiV with its direct link to the adult cohort allowed Compagno et al to assess the vertical transmission of antiretroviral drug-resistant HIV strains in CWH.⁴³

Strengths and limitations

The uniqueness of our cohort study is the prospective longitudinal data collection over more than 30 years and across generations, combining clinical, behavioural and laboratory data in conjunction with a biobank and a profound and long-standing synergy with the SHCS. Figure 3 shows the cumulative number of included children over the years.

Data from WWH are available in the SHCS from before and after pregnancy and in MoCHiV for the time during pregnancy and delivery. The link to the SHCS database provides detailed information on longitudinal maternal disease characteristics, including

treatment and drug resistance, as well as epidemiological and socioeconomic data. The transfer of a large proportion of CWH in MoCHiV to the adult cohort also allows vertically infected children to be followed well into adulthood.

The inclusion of HEU is an additional strength. These children are followed for up to 5 years, enabling research into the long-term effects and adverse effects of antiretroviral exposure during pregnancy, delivery and the postnatal period.²⁵ Additionally, stored plasma/serum, viable cells/cell pellets and placental material are available for analysis.


The standardised questionnaires monitored data Š management and close cooperation with the SHCS data centre guarantee high-quality longitudinal data. This data quality enables MoCHiV not only to answer its own research questions but also to participate actively in European and international collaborations.

Another major strength of the study is the interdisciplinary collaboration. Infectious disease specialists, gynaecologists, paediatricians and epidemiologists are represented on the MoCHiV board. This ensures of that MoCHiV procedures and questionnaires are constantly adapted to the current guidelines and standards of care.


Some limitations of this study should be noted. There is no control group of pregnant women and their CWH. There may be a selection bias, as around 30% of pregnant WWH registered by the FOPH in Switzerland do not participate in the SHCS.⁴⁴

Also, the number of patients per year is small and complete data collection also depends on the participating physicians and the completeness of the questionnaires.

Since different databases have been used and had to be brought together as part of the development **a** of MoCHiV and its integration into the SHCS and



Status Children



because various questionnaires were introduced at different times as shown in figure 1, fully standardised data are only available after 2004. This makes the analysis of cumulative data, including data prior to 2004, somewhat difficult and challenging. The relatively high number of patients lost to follow-up as shown in table 1 is an additional difficulty that complicates longitudinal analysis.

Collaboration

As described in the findings to date and strengths of the cohort, collaboration with other cohorts such as the EPPICC is already in place and is considered important. In principle, any access to cohort data or samples to answer a research question, whether internal or external, or the request for collaboration requires the approval of the scientific board. For this purpose, a structured and detailed study proposal must be submitted. Biological samples were used, for example, to assess the rate of vertical transmission of antiretroviral drug-resistant HIV strains in CWH.43 Further information regarding the cohort biobank can be found in previous publications¹² The template, submission deadlines and a description of the evaluation and decision-making process can be found on the website (http://www.shcs.ch/132-who-can-submit).

Patient and public involvement

Patient representatives have been on the scientific board for several years, ensuring active patient involvement in research. News and press releases are available on the cohort website and can be subscribed to as a newsletter.

Study participation and study information

Physicians and regional hospital centers interested in a collaboration can contact one of the local centers for more information. Patients interested in participating can contact a collaborating physician, a regional hospital or directly one of the seven outpatient clinics. The SHCS has a website covering the most important information, including all questionnaires for MoCHiV and SHCS: http://www.shcs.ch.

Author affiliations

¹Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland

²Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland

³Frauenklinik, Bürgerspital Solothurn, Solothurn, Switzerland

⁴Institute of Medical Virology, University of Zurich, Zurich, Switzerland

⁵Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland

⁶Department of Obstetrics and Gynecology, Lindenhofspital Bern, Bern, Switzerland ⁷Unit of Pediatric Infectious Diseases and Vaccinology, Department of Woman Mother and Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

⁸Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland ¹²Pediatric Infectious Diseases Unit, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals, Geneve, Switzerland

¹³Department of Obstetrics, University Hospital Basel, Basel, Switzerland
¹⁴University Children's Hospital Basel, Basel, Switzerland

¹⁵Cantonal Hospital St. Gallen, Department of Infectious Diseases, Infection Prevention and Travel Medicine, St Gallen, Switzerland

¹⁶Children's Hospital of Eastern Switzerland, Infectious Diseases and Hospital Epidemiology, St Gallen, Switzerland

X Huldrych Günthard @HGunthard

Acknowledgements We would like to express our sincere thanks to the patients and their families for their participation in the cohort, in some cases for many years. We would also like to thank the many study staff, some of whom have been part of the cohort for many years.

Collaborators Members of the Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort Study: Abela I, Aebi-Popp K, Anagnostopoulos A, Battegay M, Baumann M, Bernasconi E, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Crisinel PA, Darling K, Duppenthaler A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Francini K, Furrer H, Fux CA, Günthard HF (President of the SHCS), Hachfeld A, Haerry D (deputy of 'Positive Council'), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Huber M, Jackson-Perry D (patient representatives), Kahlert CR (Chairman of the Mother & Child Substudy), Kaiser L. Kapfhammer E. Keiser O. Klimkait T. Kohns M, Kottanattu L, Kouyos RD, Kovari H, Kusejko K (Head of Data Centre), Labhardt N, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nemeth J, Nicca D, Notter J, Paioni P, Pantaleo G, Perreau M, Polli Ch, Rauch A (Chairman of the Scientific Board), Salazar-Vizcaya L, Schmid P, Speck R, Stöckle M (Chairman of the Clinical and Laboratory Committee), Tarr P, Thanh Lecompte M, Trkola A, Wagner N, Wandeler G, Weisser M, Yerly S. Retired former senior members of SHCS and MoCHiV: Böni J, Cheseaux JJ, Francioli P (former president of the SHCS), Hirschel B, Kind C (former chairman of the Swiss Neonatal HIV study), Ledergerber B, Nadal D Rickenbach M, Rudin C (former chairman of the Swiss HIV and Pregnancy Study and MoCHiV), Schüpbach J, Siegrist C-A.

Contributors PP, AB, KK and CRK conceived the study and design; AB performed the literature searches; PP, KA-P, P-AC, AD, HFG, BMDT, LK, MS, AR, NW, IH, CR and CRK collected the data in their centres; MC, AB, AT and AS performed data extraction, assessment of bias, formal analysis under the supervision of PP, KK, CRK; PP, KK and CRK wrote the manuscript; all authors examined the results, reviewed and edited the manuscript and agreed on the final version of the manuscript. PP, KK and CRK acted as guarantors. KK and CRK are joint last authors.

Funding MoCHiV and the SHCS are supported by the Swiss National Science Foundation (grant #201369) and by the SHCS research foundation. Funding from companies is governed by the SHCS association (SHCS_Association).

Competing interests AB, AT, AS, CRK, IH, PP, NW, LK and CR declare no conflicts of interest. BMT has participated as expert for Glaxo-Smith Kline, Jansen, Medinova, Pierre-Favre. HG has received unrestricted research grants from Gilead Sciences; fees for data and safety monitoring board membership from Merck; consulting/advisory board membership fees from Gilead Sciences, ViiV Healthcare, Johnson and Johnson, Janssen, GSK and Novartis; and grants from SystemsX, and the National Institutes of Health and the Yvonne Jacob Foundation. The institution of E.B. received fees for his participation to Advisory boards and travel grants from Gilead Sciences, MSD, ViiV healthcare, Abbott, Pfizer and Sandoz. AR reports support to his institution for advisory boards and/or travel grants from MSD, Gilead Sciences, Pfizer and Moderna, and an investigator-initiated trial (IIT) grant from Gilead Sciences. All remuneration was provided outside the submitted work.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Cohort description section for further details.

Patient consent for publication Consent obtained from parent(s)/guardian(s).

Ethics approval The parent or guardian must sign a consent form for participation that has been approved by the responsible ethics committee of all participating institutions (ie, Kantonale Ethikkommission Bern, Ethikkommission Nordwest- und

Zentralschweiz, Ethikkommission Ostschweiz, Commission Cantonale d'Ethique de la Recherche sur l'être humain, Ethikkommission Zürich).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Cohort data are not publicly available due to privacy or ethical restrictions. However, MoCHiV has a data sharing process. Interested researchers should submit a detailed study proposal outlining the purpose of the data use and confirming their commitment to use the data solely for research purposes only and to maintain confidentiality. Access to data will be granted after approval by the scientific board. The open data statement is available on the website https://www.shcs.ch/294-open-data-statement-shcs.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/ licenses/by/4.0/.

ORCID iD

Christian R Kahlert http://orcid.org/0000-0002-0784-3276

REFERENCES

- Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010;39:1179–89.
- 2 Scherrer AU, Traytel A, Braun DL, et al. Cohort Profile Update: the Swiss HIV Cohort Study (SHCS). Int J Epidemiol 2022;51:33–34j.
- 3 Kind C, Brändle B, Wyler CA, et al. Epidemiology of vertically transmitted HIV-1 infection in Switzerland: results of a nationwide prospective study. Swiss Neonatal HIV Study Group. Eur J Pediatr 1992;151:442–8.
- 4 Rudin C, Camli C, Schnüriger H, et al. HIV and pregnancy. Schweiz Med Wochenschr 1995;125:2322–9.
- 5 Kusejko K, Smith D, Scherrer A, et al. Migrating a Well-Established Longitudinal Cohort Database From Oracle SQL to Research Electronic Data Entry (REDCap): data Management Research and Design Study. JMIR Form Res 2023;7:e44567.
- 6 Connor EM, Sperling RS, Gelber R, *et al.* Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med* 1994;331:1173–80.
- 7 Pädiatrische AIDS-Gruppe Schweiz (PAGS), Kommission der Schweizerischen Gesellschaft für Pädiatrie, Subkommission Klinik (SKK) der Eidgenössischen Kommission für AIDS-Fragen (EKAF), Arbeitsgruppe HIV der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe. Zidovudin Zur Prophylaxe Der HIV-Uebertragung von Der Infizierten Mutter Auf Ihr Kind. Bullletin des Bundesamtes für Gesundheitswesen, 1994:43. 746–8.
- 8 Kind C, Rudin C, Siegrist CA, et al. Effects of zidovudine prophylaxis and elective cesarean section on vertical HIV transmission, abstract #Tu.C. 442. XIth International Conference on AIDS; Vancouver, Canada, 1996
- 9 Kind C, Nadal D, Wyler CA. Mother-to-child transmission of human immunodeficiency virus type 1: influence of parity and mode of delivery. Paediatric AIDS Group of Switzerland. *Eur J Pediatr* 1995;154:542–5.
- 10 Kind C, Rudin C, Siegrist CA, et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS 1998;12:205–10.
- 11 Andiman W, Bryson Y, International Perinatal HIV Group. The Mode of Delivery and the Risk of Vertical Transmission of Human Immunodeficiency Virus Type 1 — A Meta-Analysis of 15 Prospective Cohort Studies. N Engl J Med 1999;340:977–87.

- 12 European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. *The Lancet* 1999;353:1035–9.
- 13 Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9.
- 14 Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. *The Lancet* 1999;353:863–8.
- 15 Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS 1998;12:F241–7.
- 16 Subkommission Klinik der Eidgenössischen Kommission für AIDS-Fragen, der Pädiatrischen AIDS-Gruppe Schweiz und der Schweizerischen Gesell-schaft für Gynäkologie und Geburtshilfe. Vorläufige Empfehlungen Antiretrovirale Behandlung Während Der Schwangerschaft. Bulletin des Bundesamtes für Gesundheit (BAG), 1998:44. 10–3.
- 17 Lapaire O, Irion O, Koch-Holch A, et al. Increased peri- and postelective cesarean section morbidity in women infected with human immunodeficiency virus-1: a case-controlled multicenter study. Arch Gynecol Obstet 2006;274:165–9.
- 18 Fachkommission Klinik und Therapie HIV/AIDS des BAG. HIV, Schwangerschaft Und Geburt: Ein Update Der Empfehlungen Zur Prävention Der Vertikalen HIV-Transmission. Bulletin des Bundesamt für Gesundheit, 2009:5. 69–75.
- 19 Aebi-Popp K, Mulcahy F, Glass TR, *et al.* Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery. *J Acquir Immune Defic Syndr* 2013;64:58–65.
- 20 Rudin C, Spaenhauer A, Keiser O, et al. Antiretroviral therapy during pregnancy and premature birth: analysis of Swiss data. *HIV Med* 2011;12:228–35.
- 21 Townsend C, Schulte J, Thorne C, *et al.* Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. *BJOG* 2010;117:1399–410.
- 22 Lumbreras Areta M, Migliorelli Falcone FE, Rudin C, et al. Trends in preterm birth in women living with HIV in Switzerland over the last three decades: A multicentric, prospective, cohort study. *HIV Med* 2024;25:958–66.
- 23 Patel K, Huo Y, Jao J, et al. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. N Engl J Med 2022;387:799–809.
- 24 Throne C, Rudin C, Newell M, *et al*. Combination antiretroviral therapy and duration of pregnancy. *AIDS* 2000;14:2913–20.
- 25 Greiter BM, Kahlert CR, Eberhard N, et al. Lymphocyte Subsets in HIV-Exposed Uninfected Infants: the Impact of Neonatal Postexposure Prophylaxis With Zidovudine. Open Forum Infect Dis 2020;7:ofaa108.
- 26 Rudin C, Senn HP, Berger R, et al. Repeated polymerase chain reaction complementary to other conventional methods for early detection of HIV infection in infants born to HIV-infected mothers. Eur J Clin Microbiol Infect Dis 1991;10:146–56.
- 27 Schüpbach J, Böni J, Tomasik Z, et al. Sensitive detection and early prognostic significance of p24 antigen in heat-denatured plasma of human immunodeficiency virus type 1-infected infants. Swiss Neonatal HIV Study Group. J Infect Dis 1994;170:318–24.
- 28 Schüpbach J, Tomasik Z, Jendis J, et al. IgG, IgM, and IgA response to HIV in infants born to HIV-1 infected mothers. Swiss Neonatal HIV Study Group. J Acquir Immune Defic Syndr (1988) 1994;7:421–7.
- 29 Schüpbach J, Wunderli W, Kind C, et al. Frequent detection of HIVand IgG-specific IgM and IgA antibodies in HIV-positive cord-blood sera: fine analysis by western blot. *AIDS* 1989;3:583–9.
- 30 Schüpbach J. Measurement of HIV-1 p24 antigen by signalamplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA. *AIDS Rev* 2002;4:83–92.
- 31 Empfehlungen Der Eidgenössischen Kommission Für Sexuelle Gesundheit (EKSG) Zur Prävention Der HIV-Übertragung von Der Mutter Zum Kind. Arbeitsgruppe MoCHiV. Bulletin des Bundesamt für Gesundheit, 2016:4. 80–1.
- 32 Abstracts of the 17th European AIDS Conference, Basel, Switzerland, 6-9 November 2019. *HIV Med* 2019;20:3–316.
- 33 Kahlert C, Aebi-Popp K, Bernasconi E, et al. Is breastfeeding an equipoise option in effectively treated HIV-infected mothers in a highincome setting? Swiss Med Wkly 2018;148.
- 34 Crisinel PA, Kusejko K, Kahlert CR, et al. Successful implementation of new Swiss recommendations on breastfeeding of infants born

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

to women living with HIV. *Eur J Obstet Gynecol Reprod Biol* 2023;283:86–9.

- 35 Aebi-Popp K, Kahlert CR, Crisinel P-A, et al. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. J Antimicrob Chemother 2022;77:3436–42.
- 36 Aebi-Popp K, Kouyos R, Bertisch B, et al. Postnatal retention in HIV care: insight from the Swiss HIV Cohort Study over a 15-year observational period. *HIV Med* 2016;17:280–8.
- 37 Paioni P, Aebi-Popp K, Martinez de Tejada B, et al. Viral suppression and retention in HIV care during the postpartum period among women living with HIV: a longitudinal multicenter cohort study. Lancet Reg Health Eur 2023;31:100656.
- 38 Rudin C, Burri M, Shen Y, et al. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. *Pediatr Infect Dis J* 2008;27:431–7.
- 39 Rudin C, Wolbers M, Nadal D, et al. Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1infected children. Arch Dis Child 2010;95:478–81.

- 40 Nadal D, Steiner F, Cheseaux JJ, et al. Ritonavir promotes increased growth in HIV-infected children. Paediatric AIDS Group of Switzerland. AIDS 1998;12:2356–7.
- 41 Nadal D, Steiner F, Cheseaux JJ, et al. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland. *Infection* 2000;28:287–96.
- 42 Steiner F, Kind C, Aebi C, et al. Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors. Eur J Pediatr 2001;160:611–6.
- 43 Compagno F, Naegele K, Kahlert CR, et al. The rate of mother-tochild transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study. Swiss Med Wkly 2019;149.
- 44 Grawe C, Gebhardt M, Aebi-Popp K, et al. Pregnant women diagnosed with hiv in switzerland: longitudinal evaluation of public reporting and recruitment to the swiss hiv cohort study (SHCS) and mother and child hiv cohort study (MoCHiV). Free Communications FM V/ 52nd Annual Congress Swiss Society for Gynecology and Obstetrics SGGG 2018.

Supplementary Table 1 Baseline characteristics of women giving birth in SHCS and MoCHiV

between 01/1986 and 12/2022

	Total	Registered in MoCHiV	Not registered in MoCHiV	p-value ^a
Mothers				
	1209	1041	168	
Total mothers registered	in SHCS		1	< 0.001
Active patients	777 (64 %)	647 (62 %)	130 (77 %)	
Voluntary	115 (10 %)	109 (10 %)	6 (4 %)	
Died	59 (5 %)	55 (5 %)	4 (2 %)	
Lost to follow-up	258 (21 %)	230 (22 %)	28 (17 %)	
Age in years at HIV diag	nosis		1	0.015
Median (IQR)	27 [23, 31]	26 [23, 31]	28 [23, 32]	
Ethnicity			•	0.047
Black	540 (45 %)	455 (44 %)	85 (51 %)	
White	513 (42 %)	445 (43 %)	68 (40 %)	
Asian	72 (6 %)	65 (6 %)	7 (4 %)	
Hispano-American	45 (4 %)	37 (4 %)	8 (5 %)	
Unknown	39 (3 %)	39 (4 %)	0 (0 %)	
Source of HIV infection			1	0.003
Heterosexual Contact	951 (79 %)	818 (79 %)	133 (79 %)	
Intravenous drug use	164 (14 %)	152 (15 %)	12 (7 %)	
Perinatal transmission	22 (2 %)	18 (2 %)	4 (2 %)	
Blood Products	19 (2 %)	14 (1 %)	5 (3 %)	
Unknown	53 (4 %)	39 (4 %)	14 (8 %)	
Viral load at delivery			1	< 0.001
< 50 copies/ml	663 (55 %)	577 (55 %)	86 (51 %)	
50- 1000 copies/ml	116 (10 %)	106 (10 %)	10 (6 %)	
>1000 copies/ml	119 (10 %)	114 (11 %)	5 (3 %)	
Log10 of median if >	4 [3.5, 4.4]	4 [3.5, 4.4]	4.1 [3.5, 4.3]	
Unknown	311 (26 %)	244 (23 %)	67 (40 %)	

^a Chi-Square test for categorical variables and Welch's t-test for continuous variable were used

Abbreviations: IQR, interquartile range; MoCHiV, Swiss Mother and Child HIV Cohort Study; SHCS, Swiss

HIV Cohort Study

